Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA330497

Local Sample ID:	GR_386
Subject ID:	SU003160
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Gender:	Male and female

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003169
Treatment Summary:	All patients were given neo-RT in a total dose of 39-54Gy. Tissue samples were collected between 2012 and 2014, directly during a standard surgical treatment; resected tissue samples were immediately frozen and kept at -80 °C until analysis performed in 2020. The histology of three tissue slices (from the edges and center of the studied tissue sample) was assessed by an experienced pathologist for the percentage of tumor cells in each case. TRG assessed routinely in resected tumors reflected the area of residual tumor cells compared to the fibrotic area: TRG0 - complete response/no residual tumor, TRG1 - 10% of residual tumor, TRG2 - 10-50% of residual tumor, and TRG3 - >50% of residual tumor. Depending on the response to the treatment and the presence of tumor cells, collected samples were classified into two groups: good responders (GR) – 12 patients with RT-sensitive tumors (TRG 0-1), and poor responders (PR) - 12 patients with RT-resistant tumors (TRG 2-3).

Treatment ID:

TR003169

Treatment Summary:

All patients were given neo-RT in a total dose of 39-54Gy. Tissue samples were collected between 2012 and 2014, directly during a standard surgical treatment; resected tissue samples were immediately frozen and kept at -80 °C until analysis performed in 2020. The histology of three tissue slices (from the edges and center of the studied tissue sample) was assessed by an experienced pathologist for the percentage of tumor cells in each case. TRG assessed routinely in resected tumors reflected the area of residual tumor cells compared to the fibrotic area: TRG0 - complete response/no residual tumor, TRG1 - 10% of residual tumor, TRG2 - 10-50% of residual tumor, and TRG3 - >50% of residual tumor. Depending on the response to the treatment and the presence of tumor cells, collected samples were classified into two groups: good responders (GR) – 12 patients with RT-sensitive tumors (TRG 0-1), and poor responders (PR) - 12 patients with RT-resistant tumors (TRG 2-3).